Updated overall survival (OS) and genomic analysis from a single-arm phase II study of dabrafenib (D) plus trametinib (T) in patients (pts) with BRAF V600E mutant (Mut) metastatic non-small cell lung cancer (NSCLC).

Authors
Publication date
20 May 2020
Publisher

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Dissertations of the University of Groningen

    redirect
    oaioai:pure.rug.nl:publications/6...
    Last time updated on 02/06/2022

    NARCIS

    redirect
    Last time updated on 29/05/2021

    University of Groningen

    redirect
    oaioai:pure.rug.nl:publications/6...
    Last time updated on 24/11/2020

    NARCIS

    redirect
    Last time updated on 29/05/2021